IRIS PubliCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.321
EU - Europa 3.565
AS - Asia 1.060
SA - Sud America 57
AF - Africa 46
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 9.074
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.276
DE - Germania 1.029
SE - Svezia 708
CN - Cina 658
UA - Ucraina 417
IT - Italia 359
IE - Irlanda 224
FR - Francia 206
PL - Polonia 166
SG - Singapore 144
GB - Regno Unito 138
IN - India 104
FI - Finlandia 100
RU - Federazione Russa 68
TR - Turchia 52
BE - Belgio 39
JP - Giappone 33
CI - Costa d'Avorio 32
NL - Olanda 22
RO - Romania 22
ES - Italia 19
CA - Canada 17
EC - Ecuador 16
CL - Cile 15
HK - Hong Kong 15
MX - Messico 15
AU - Australia 13
IL - Israele 13
BR - Brasile 11
CH - Svizzera 10
PE - Perù 8
CZ - Repubblica Ceca 7
IR - Iran 7
BZ - Belize 6
KE - Kenya 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BG - Bulgaria 5
GR - Grecia 5
KR - Corea 5
VN - Vietnam 5
EU - Europa 4
PR - Porto Rico 4
TH - Thailandia 4
CO - Colombia 3
HU - Ungheria 3
IQ - Iraq 3
LK - Sri Lanka 3
PT - Portogallo 3
AR - Argentina 2
AT - Austria 2
GA - Gabon 2
JO - Giordania 2
LU - Lussemburgo 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BF - Burkina Faso 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 9.074
Salva come PNG Salva come JPEG
Città #
Chandler 891
Ashburn 398
Jacksonville 281
San Mateo 230
Dublin 215
Wilmington 155
Ann Arbor 154
Warsaw 143
Nanjing 141
Houston 118
Dearborn 116
Woodbridge 114
New York 97
Cattolica 96
Boston 95
Singapore 92
Princeton 71
Redwood City 69
Beijing 64
Lawrence 61
Milan 61
Chicago 53
Nürnberg 53
Fairfield 49
Marseille 49
Seattle 47
Bremen 46
Nanchang 45
Izmir 44
Moscow 44
Fuzhou 41
Hangzhou 37
Redmond 37
Brussels 33
Abidjan 32
Shanghai 31
Mountain View 30
Shenyang 27
Norwalk 25
Tianjin 25
Boardman 24
Hebei 24
Zhengzhou 24
Changsha 23
Rome 21
London 20
Kunming 18
Leawood 16
Jiaxing 15
Millbury 15
Cambridge 14
University Park 14
Los Angeles 13
Hong Kong 12
Munich 12
Pune 12
Falls Church 11
Philadelphia 11
Washington 11
Berlin 10
Frankfurt am Main 10
Fremont 10
Dagenham 9
Málaga 9
San Jose 9
Tokyo 9
Bologna 8
Guangzhou 8
Helsinki 8
Indiana 8
Kraków 8
Saint Louis 8
Amsterdam 7
Buffalo 7
Hefei 7
Lancaster 7
Lanzhou 7
Loja 7
Arlington Heights 6
Belize City 6
Iasi 6
Nairobi 6
New Delhi 6
Ningbo 6
San Francisco 6
Augusta 5
Cleja 5
Edinburgh 5
Edmonton 5
Guayaquil 5
Jinan 5
Lima 5
Madrid 5
Mexico City 5
Rzeszów 5
Tel Aviv 5
Toronto 5
Zurich 5
Andover 4
Ban Kho 4
Totale 4.991
Salva come PNG Salva come JPEG
Nome #
Myasthenia gravis 206
International consensus guidance for management of myasthenia gravis: Executive summary 199
Single-centre 40-year results of redo operation for recurrent thymomas. 186
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 142
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 138
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 138
Thymoma in patients with MG: characteristics and long-term outcome 130
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 130
When myasthenia gravis is not all. 130
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 127
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 125
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 123
SFEMG: A piece in the diagnostic puzzle of myasthenia 122
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 113
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 113
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 106
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 105
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 105
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 102
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 101
Anti-AChR-negative myasthenia gravis: clinical and immunological features 98
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 96
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 96
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 96
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 95
A Genome-wide Association Study of Myasthenia Gravis 94
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 93
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 89
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 88
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 86
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 85
Multiple paraneoplastic diseases associated with thymoma. 84
Determinants of cognitive impairment in elderly myasthenia gravis patients 84
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 83
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 81
Response to therapy in myasthenia gravis with anti-MuSK antibody 80
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 80
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 79
BAFF serum levels in myasthenia gravis: effects of therapy 78
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 78
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 78
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 77
Diagnostic features and subtyping of thymoma lymph node metastases 76
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 75
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 74
Prognostic grading after complete resection for thymic malignancies 73
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 72
Clinical heterogeneity of seronegative myasthenia gravis 72
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 72
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 72
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 71
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 71
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 69
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 67
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 67
Immunosuppressive therapies in myasthenia gravis 66
Myasthenia gravis with antibodies to MuSK: an update 66
Spontaneous recovery from anti-NMDAR encephalitis 65
Acquired myasthenia gravis in childhood. 65
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 65
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 65
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 64
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 64
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 63
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 63
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 63
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 63
A practical guide to the recognition and management of myasthenia gravis 60
Antibody-phenotype correlation in stiff-person syndrome 60
Early-onset myasthenia gravis: clinical characteristics and response to therapy 60
Risk of cancer in patients with myasthenia gravis 59
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 59
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 58
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 58
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 58
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase 57
Myasthenia gravis during interferon alfa therapy 56
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 56
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 55
Minimal manifestation status and prednisone withdrawal in the MGTX trial 55
Course and treatment of myasthenia gravis during pregnancy 54
Risk factors for tumor occurrence in patients with myasthenia gravis. 54
An update on Thymectomy in Myasthenia Gravis 54
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 54
Myasthenia gravis and associated autoimmune diseases 53
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 53
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 53
In sickness and in health: when myasthenia gravis is a conjugal matter 53
Thymoma recurrences in myasthenia gravis patients 52
The tiles make a puzzle but the single tile is not the puzzle: The need for a global assessment of the patient 52
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 52
Imatinib mesylate in thymic epithelial malignancies. 50
MuSK autoantibodies in myasthenia gravis detected by cell based assay-A multinational study 49
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 49
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 49
Long-term results of corticosteroid therapy in patients with myasthenia gravis 47
Familial autoimmune myasthenia gravis: report of four families 47
242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019 47
Controversies in Ocular Myasthenia Gravis 47
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 46
Totale 8.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.148 242 50 54 36 91 86 161 39 80 62 142 105
2020/2021987 66 105 19 99 135 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/202514 14 0 0 0 0 0 0 0 0 0 0 0
Totale 9.239